Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Planchard

Showing results (41-50 of 243) with videos related to

Pageof 25
Sort By:
Bulletin Du Cancer|August 4, 2015
[3rd generation's TKI in lung cancer non-small cell EGFR-mutated having acquired a secondary T790M resistance]Solenn Brosseau, Marie Viala, Andréa Varga, et al.
NPJ Precision Oncology|April 16, 2024
BRAF<sup>V600E</sup>-mutant metastatic NSCLC: disease overview and treatment landscapeDavid Planchard, Rachel E Sanborn, Marcelo V Negrao, et al.
Frontiers in Oncology|June 28, 2021
Durable Response to the Combination of Atezolizumab With Platinum-Based Chemotherapy in an Untreated Non-Smoking Lung Adenocarcinoma Patient With <i>BRAF</i> V600E Mutation: A Case ReportXiaomin Niu, Yingjia Sun, David Planchard, et al.
Annales De Pathologie|January 19, 2016
[PD-L1 expression: An emerging biomarker in non-small cell lung cancer]Julien Adam, David Planchard, Aurélien Marabelle, et al.
Plos Computational Biology|June 17, 2025
Multimodal CustOmics: A unified and interpretable multi-task deep learning framework for multimodal integrative data analysis in oncologyHakim Benkirane, Maria Vakalopoulou, David Planchard, et al.
Cancers|November 11, 2022
KRAS in NSCLC: State of the Art and Future PerspectivesPriscilla Cascetta, Arianna Marinello, Chiara Lazzari, et al.
Cancer Treatment Reviews|May 6, 2018
BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wallAlessandro Leonetti, Francesco Facchinetti, Giulio Rossi, et al.
Cancer Treatment Reviews|April 15, 2023
Acquired resistance mechanisms to osimertinib: The constant battleZiad Zalaquett, Maria Catherine Rita Hachem, Yara Kassis, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 9, 2017
Factors which modulate the rates of skeletal muscle mass loss in non-small cell lung cancer patients: a pilot studyPhilippe Atlan, Mohamed Amine Bayar, Emilie Lanoy, et al.
Cancer Treatment Reviews|October 23, 2024
Neoadjuvant immunotherapy strategies for resectable non-small cell lung cancer (NSCLC): Current evidence among special populations and future perspectivesClaudia Parisi, Pamela Abdayem, Marco Tagliamento, et al.
Pageof 25

Showing results (41-50 of 243) with videos related to

Sort By:
Pageof 25
Bulletin Du Cancer|August 4, 2015
[3rd generation's TKI in lung cancer non-small cell EGFR-mutated having acquired a secondary T790M resistance]Solenn Brosseau, Marie Viala, Andréa Varga, et al.
NPJ Precision Oncology|April 16, 2024
BRAF<sup>V600E</sup>-mutant metastatic NSCLC: disease overview and treatment landscapeDavid Planchard, Rachel E Sanborn, Marcelo V Negrao, et al.
Frontiers in Oncology|June 28, 2021
Durable Response to the Combination of Atezolizumab With Platinum-Based Chemotherapy in an Untreated Non-Smoking Lung Adenocarcinoma Patient With <i>BRAF</i> V600E Mutation: A Case ReportXiaomin Niu, Yingjia Sun, David Planchard, et al.
Annales De Pathologie|January 19, 2016
[PD-L1 expression: An emerging biomarker in non-small cell lung cancer]Julien Adam, David Planchard, Aurélien Marabelle, et al.
Plos Computational Biology|June 17, 2025
Multimodal CustOmics: A unified and interpretable multi-task deep learning framework for multimodal integrative data analysis in oncologyHakim Benkirane, Maria Vakalopoulou, David Planchard, et al.
Cancers|November 11, 2022
KRAS in NSCLC: State of the Art and Future PerspectivesPriscilla Cascetta, Arianna Marinello, Chiara Lazzari, et al.
Cancer Treatment Reviews|May 6, 2018
BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wallAlessandro Leonetti, Francesco Facchinetti, Giulio Rossi, et al.
Cancer Treatment Reviews|April 15, 2023
Acquired resistance mechanisms to osimertinib: The constant battleZiad Zalaquett, Maria Catherine Rita Hachem, Yara Kassis, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 9, 2017
Factors which modulate the rates of skeletal muscle mass loss in non-small cell lung cancer patients: a pilot studyPhilippe Atlan, Mohamed Amine Bayar, Emilie Lanoy, et al.
Cancer Treatment Reviews|October 23, 2024
Neoadjuvant immunotherapy strategies for resectable non-small cell lung cancer (NSCLC): Current evidence among special populations and future perspectivesClaudia Parisi, Pamela Abdayem, Marco Tagliamento, et al.
Pageof 25